Impact of a Positive Viral Polymerase Chain Reaction on Outcomes of Chronic Obstructive Pulmonary Disease (COPD) Exacerbations.
COPD
chronic obstructive pulmonary disease
length of stay
respiratory virus panel
Journal
International journal of environmental research and public health
ISSN: 1660-4601
Titre abrégé: Int J Environ Res Public Health
Pays: Switzerland
ID NLM: 101238455
Informations de publication
Date de publication:
02 11 2020
02 11 2020
Historique:
received:
07
09
2020
revised:
19
10
2020
accepted:
28
10
2020
entrez:
5
11
2020
pubmed:
6
11
2020
medline:
20
1
2021
Statut:
epublish
Résumé
More than 15 million adults in the USA have chronic obstructive pulmonary disease. Chronic obstructive pulmonary disease (COPD) places a high burden on the healthcare system. Many hospital admissions are due to an exacerbation, which is suspected to be from a viral cause. The purpose of this analysis was to compare the outcomes of patients with a positive and negative respiratory virus panel who were admitted to the hospital with COPD exacerbations. This retrospective cohort study was conducted in the Geisinger Healthcare System. The dataset included 2729 patient encounters between 1 January 2006 and 30 November 2017. Hospital length of stay was calculated as the discrete number of calendar days a patient was in the hospital. Patient encounters with a positive and negative respiratory virus panel were compared using Pearson's chi-square or Fisher's exact test for categorical variables and Student's t-test or Wilcoxon rank-sum tests for continuous variables. There were 1626 patients with a total of 2729 chronic obstructive pulmonary disease exacerbation encounters. Nineteen percent of those encounters ( This study shows that a positive respiratory virus panel is associated with increased length of hospital stay. Early diagnosis of chronic obstructive pulmonary disease exacerbation patients with positive viral panel would help identify patients with a longer length of stay.
Identifiants
pubmed: 33147795
pii: ijerph17218072
doi: 10.3390/ijerph17218072
pmc: PMC7662648
pii:
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : NCATS NIH HHS
ID : UL1 TR001863
Pays : United States
Références
J Allergy Clin Immunol. 2010 Jun;125(6):1369-1378.e2
pubmed: 20430426
Thorax. 2003 Jan;58(1):37-42
pubmed: 12511718
Am J Respir Crit Care Med. 2013 Feb 15;187(4):347-65
pubmed: 22878278
ERJ Open Res. 2016 Mar 05;2(1):
pubmed: 27730166
Chest. 2006 Feb;129(2):317-24
pubmed: 16478847
Am J Manag Care. 2017 Aug 1;23(8):e253-e258
pubmed: 29087152
Am J Respir Crit Care Med. 2000 May;161(5):1608-13
pubmed: 10806163
Eur Respir J. 2007 Jun;29(6):1224-38
pubmed: 17540785
Respir Med. 2011 Mar;105(3):454-60
pubmed: 20869226
Am J Respir Crit Care Med. 2001 Nov 15;164(10 Pt 2):S71-5
pubmed: 11734471
Ther Adv Respir Dis. 2016 Apr;10(2):158-74
pubmed: 26611907
Thorax. 2013 Aug;68(8):717-23
pubmed: 23422214
COPD. 2015;12(6):636-42
pubmed: 26263035
Int J Chron Obstruct Pulmon Dis. 2016 Mar 02;11:455-65
pubmed: 27042038
J Clin Virol. 2014 Oct;61(2):181-8
pubmed: 25066886
Int J Chron Obstruct Pulmon Dis. 2014 Jan 20;9:99-105
pubmed: 24477272
Scand J Immunol. 2018 Jul;88(1):e12674
pubmed: 29752829
Am J Respir Crit Care Med. 2001 Nov 1;164(9):1618-23
pubmed: 11719299
Int J Chron Obstruct Pulmon Dis. 2015 Oct 20;10:2257-63
pubmed: 26527871
Chest. 2000 Nov;118(5):1278-85
pubmed: 11083675
J Clin Virol. 2009 Oct;46(2):129-33
pubmed: 19665425
Am Fam Physician. 2006 Feb 15;73(4):669-76
pubmed: 16506711
Proc Am Thorac Soc. 2004;1(2):115-20
pubmed: 16113423
Int J Chron Obstruct Pulmon Dis. 2016 Mar 17;11:577-83
pubmed: 27042046
Am J Respir Crit Care Med. 2006 May 15;173(10):1114-21
pubmed: 16484677
Respir Care. 2018 May;63(5):591-600
pubmed: 29692353
Chest. 2015 Jan;147(1):31-45
pubmed: 25058738
Am J Respir Crit Care Med. 1999 Sep;160(3):791-5
pubmed: 10471598
J Int Med Res. 2018 Sep;46(9):3890-3902
pubmed: 29950127